203 related articles for article (PubMed ID: 26468869)
1. Increased Serum Brain-derived Neurotrophic Factor in Multiple Sclerosis Patients on Interferon-β and Its Impact on Functional Abilities.
Mehrpour M; Akhoundi FH; Delgosha M; Keyvani H; Motamed MR; Sheibani B; Meysamie A
Neurologist; 2015 Oct; 20(4):57-60. PubMed ID: 26468869
[TBL] [Abstract][Full Text] [Related]
2. Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment.
Guerrero AL; Martín-Polo J; Laherrán E; Gutiérrez F; Iglesias F; Tejero MA; Rodríguez-Gallego M; Alcázar C
Eur J Neurol; 2008 Apr; 15(4):394-7. PubMed ID: 18312403
[TBL] [Abstract][Full Text] [Related]
3. Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis.
Sternberg Z; Leung C; Sternberg D; Yu J; Hojnacki D
Cardiovasc Ther; 2014 Apr; 32(2):33-9. PubMed ID: 24119301
[TBL] [Abstract][Full Text] [Related]
4. Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial.
Mokhber N; Azarpazhooh A; Orouji E; Rao SM; Khorram B; Sahraian MA; Foroghipoor M; Gharavi MM; Kakhi S; Nikkhah K; Azarpazhooh MR
J Neurol Sci; 2014 Jul; 342(1-2):16-20. PubMed ID: 24841321
[TBL] [Abstract][Full Text] [Related]
5. Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients.
Lalive PH; Kantengwa S; Benkhoucha M; Juillard C; Chofflon M
J Neuroimmunol; 2008 Jul; 197(2):147-51. PubMed ID: 18555540
[TBL] [Abstract][Full Text] [Related]
6. Interferon Beta-1a and intravenous immunoglobulin treatment for multiple sclerosis in Iran.
Kalanie H; Gharagozli K; Hemmatie A; Ghorbanie M; Kalanie AR
Eur Neurol; 2004; 52(4):202-6. PubMed ID: 15539773
[TBL] [Abstract][Full Text] [Related]
7. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins.
Sarchielli P; Zaffaroni M; Floridi A; Greco L; Candeliere A; Mattioni A; Tenaglia S; Di Filippo M; Calabresi P
Mult Scler; 2007 Apr; 13(3):313-31. PubMed ID: 17439900
[TBL] [Abstract][Full Text] [Related]
8. Interferon-beta therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism.
Azoulay D; Mausner-Fainberg K; Urshansky N; Fahoum F; Karni A
J Neuroimmunol; 2009 Jun; 211(1-2):114-9. PubMed ID: 19419774
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis.
Etemadifar M; Janghorbani M; Shaygannejad V
Acta Neurol Scand; 2006 May; 113(5):283-7. PubMed ID: 16629762
[TBL] [Abstract][Full Text] [Related]
10. Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse.
Frota ER; Rodrigues DH; Donadi EA; Brum DG; Maciel DR; Teixeira AL
Neurosci Lett; 2009 Aug; 460(2):130-2. PubMed ID: 19477225
[TBL] [Abstract][Full Text] [Related]
11. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study.
Flechter S; Vardi J; Finkelstein Y; Pollak L
Isr Med Assoc J; 2007 Jun; 9(6):457-9. PubMed ID: 17642394
[TBL] [Abstract][Full Text] [Related]
12. Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial.
Ehling R; Di Pauli F; Lackner P; Rainer C; Kraus V; Hegen H; Lutterotti A; Kuenz B; De Zordo T; Schocke M; Glatzl S; Löscher WN; Deisenhammer F; Reindl M; Berger T
J Neuroimmunol; 2015 Oct; 287():98-105. PubMed ID: 26439969
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic effect of Avonex, Rebif and Betaferon on EDSS and relapse in multiple sclerosis: a comparative study.
Mazdeh M; Afzali S; Jaafari MR
Acta Med Iran; 2010; 48(2):83-8. PubMed ID: 21132998
[TBL] [Abstract][Full Text] [Related]
14. Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study.
Shirani A; Zhao Y; Karim ME; Petkau J; Gustafson P; Evans C; Kingwell E; van der Kop ML; Oger J; Tremlett H
Eur J Neurol; 2014 Jun; 21(6):835-44. PubMed ID: 24351059
[TBL] [Abstract][Full Text] [Related]
15. Increased serum levels of brain-derived neurotrophic factor in autism spectrum disorder.
Wang M; Chen H; Yu T; Cui G; Jiao A; Liang H
Neuroreport; 2015 Aug; 26(11):638-41. PubMed ID: 26103118
[TBL] [Abstract][Full Text] [Related]
16. The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment.
Lindquist S; Hassinger S; Lindquist JA; Sailer M
Mult Scler; 2011 Jul; 17(7):851-66. PubMed ID: 21561957
[TBL] [Abstract][Full Text] [Related]
17. Serum brain-derived neurotropic factor level predicts adverse clinical outcomes in patients with heart failure.
Fukushima A; Kinugawa S; Homma T; Masaki Y; Furihata T; Yokota T; Matsushima S; Takada S; Kadoguchi T; Oba K; Okita K; Tsutsui H
J Card Fail; 2015 Apr; 21(4):300-6. PubMed ID: 25639689
[TBL] [Abstract][Full Text] [Related]
18. Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study.
Dhib-Jalbut S; Sumandeep S; Valenzuela R; Ito K; Patel P; Rametta M
J Neuroimmunol; 2013 Jan; 254(1-2):131-40. PubMed ID: 22999187
[TBL] [Abstract][Full Text] [Related]
19. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
[TBL] [Abstract][Full Text] [Related]
20. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
